作者
Filippos Triposkiadis, Javed Butler, Francois M Abboud, Paul W Armstrong, Stamatis Adamopoulos, John J Atherton, Johannes Backs, Johann Bauersachs, Daniel Burkhoff, Robert O Bonow, Vijay K Chopra, Rudolf A De Boer, Leon De Windt, Nazha Hamdani, Gerd Hasenfuss, Stephane Heymans, Jean-Sebastien Hulot, Marvin Konstam, Richard T Lee, Wolfgang A Linke, Ida G Lunde, Alexander R Lyon, Christoph Maack, Douglas L Mann, Alexandre Mebazaa, Robert J Mentz, Petros Nihoyannopoulos, Zoltan Papp, John Parissis, Thierry Pedrazzini, Giuseppe Rosano, Jean Rouleau, Petar M Seferovic, Ajay M Shah, Randall C Starling, Carlo G Tocchetti, Jean-Noel Trochu, Thomas Thum, Faiez Zannad, Dirk L Brutsaert, Vincent F Segers, Gilles W De Keulenaer
发表日期
2019/7/7
来源
European heart journal
卷号
40
期号
26
页码范围
2155-2163
出版商
Oxford University Press
简介
Randomized clinical trials initially used heart failure (HF) patients with low left ventricular ejection fraction (LVEF) to select study populations with high risk to enhance statistical power. However, this use of LVEF in clinical trials has led to oversimplification of the scientific view of a complex syndrome. Descriptive terms such as ‘HFrEF’ (HF with reduced LVEF), ‘HFpEF’ (HF with preserved LVEF), and more recently ‘HFmrEF’ (HF with mid-range LVEF), assigned on arbitrary LVEF cut-off points, have gradually arisen as separate diseases, implying distinct pathophysiologies. In this article, based on pathophysiological reasoning, we challenge the paradigm of classifying HF according to LVEF. Instead, we propose that HF is a heterogeneous syndrome in which disease progression is associated with a dynamic evolution of functional and structural changes leading to unique disease trajectories creating a spectrum of …
引用总数
20182019202020212022202320241145156545020
学术搜索中的文章